These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid. Nakanishi K, Zbar B, Borsos T, Glenn G. Cancer Res; 1986 Aug; 46(8):3886-90. PubMed ID: 3089581 [Abstract] [Full Text] [Related]
3. Plasma therapy of primary rat mammary carcinoma: antitumor activity of tumor-bearer plasma adsorbed against inactivated CNBr sepharose or protein A-sepharose. Sukumar S, Zbar B, Terata N, Langone JJ. J Biol Response Mod; 1984 Aug; 3(3):303-15. PubMed ID: 6379113 [Abstract] [Full Text] [Related]
4. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. J Clin Invest; 1975 Sep; 56(3):740-50. PubMed ID: 808560 [Abstract] [Full Text] [Related]
5. Receptors for C3 on rat peritoneal mast cells. Sher A, McIntyre SL. J Immunol; 1977 Aug; 119(2):722-5. PubMed ID: 407303 [Abstract] [Full Text] [Related]
6. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement. Inada K. Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130 [Abstract] [Full Text] [Related]
9. Studies of the alternate pathway in chelated serum. Forsgren A, Mclean RH, Michael AF, Quie PG. J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816 [Abstract] [Full Text] [Related]
10. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway. Hidvégi T, Füst G, Rajnavölgyi E, Kulics J, Gergely J. Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572 [Abstract] [Full Text] [Related]
11. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum. Hill AW, Shears AL, Hibbitt KG. Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177 [Abstract] [Full Text] [Related]
14. Antibody-independent interactions between Escherichia coli J5 and human complement components. Betz SJ, Isliker H. J Immunol; 1981 Nov; 127(5):1748-54. PubMed ID: 6795260 [Abstract] [Full Text] [Related]
15. Hemolytic plate assay for quantification of active human complement component C3 using methylamine-treated plasma as complement source. Ploug M, Jessen TE, Welinder KG, Barkholt V. Anal Biochem; 1985 May 01; 146(2):411-7. PubMed ID: 3927773 [Abstract] [Full Text] [Related]
18. Human seminal plasma inhibition of complement. Petersen BH, Lammel CJ, Stites DP, Brooks GF. J Lab Clin Med; 1980 Oct 01; 96(4):582-91. PubMed ID: 6775032 [Abstract] [Full Text] [Related]
19. Disseminated intravascular coagulation induced by Liquoid in the rat. II. Effect of heparin on hematologic and complement abnormalities and renal lesions studied by light, fluorescence, and electron microscopy. Urizar RE, Sherer G, Tartaglia A, Pickering RJ, Dodds WJ. Lab Invest; 1976 May 01; 34(5):510-5. PubMed ID: 1271752 [Abstract] [Full Text] [Related]
20. Evidence for restriction of the ability of complement to lyse homologous erythrocytes. Houle JJ, Hoffmann EM. J Immunol; 1984 Sep 01; 133(3):1444-52. PubMed ID: 6430999 [Abstract] [Full Text] [Related] Page: [Next] [New Search]